Medacta Group (FRA:6MD) Moat Score: 0/10 (As of Jun. 25, 2026)


FRA:6MD Medacta Group SA FRA:6MD
91 GF Score
Price €143.00
GF Value €178.79
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medacta Group Moat Score?

Medacta Group has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Medacta Group has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Medacta Group might have No Moat - No discernible moat.

Medacta Group  (FRA:6MD) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Medacta Group Moat Score Related Terms

FRA:6MD
91GF Score
Medacta Group SA FRA:6MD
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medacta Group (FRA:6MD) Overvalued in 2026?

Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued. The current stock price of €143.00 is trading 20% below its estimated GF Value™ of €178.79. GuruFocus considers Medacta Group to be Modestly Undervalued.

Key valuation signals for FRA:6MD:

  • Moat Score: 0
  • GF Value™: €178.79 vs. price of €143.00 (20% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the FRA:6MD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medacta Group Business Description

Address Strada Regina 34, Castel San Pietro, Ticino, CHE, 6874
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
91GF Score

Get the complete analysis for FRA:6MD

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€143.00
Price
€178.79
GF Value